HC Andersen Capital releases new Ascelia Pharma investment case.
Ascelia Pharma's Phase 3 pipeline product, Orviglance, addresses an unmet need in a market estimated to be USD 500-600m annually. Being a diagnostic product and supported by strong Phase 2 data, there is a solid foundation for obtaining market approval after Phase 3 (completion expected in 2022). The market, however, currently assesses a lower than 25 pct. chance it happens. This implies a large potential if approved.
Read HC Andersen Capital's investment case here (https://hcandersencapital.dk/investment-case/ascelia-pharma-24-marts-2022/).
This is a press release from HC ANDERSEN CAPITAL, https://hcandersencapital.dk (http://www.hcandersencapital.dk).